UHPLC-HRMS-based Metabolomic and Lipidomic Characterization of Glioma Cells in Response to Anlotinib

Overview

Journal Sci Rep

Specialty Science

Date 2023 May 17

PMID 37198251

Authors

Yingying Shi

Zhuolun Li

Qiuzheng Du

Wenxi Li

Jiyun Liu

Qingquan Jia

Lianping Xue

Xiaojian Zhang

Zhi Sun

Affiliations

Soon will be listed here.

Abstract

Anlotinib, as a promising oral small-molecule antitumor drug, its role in glioma has been only reported in a small number of case reports. Therefore, anlotinib has been considered as a promising candidate in glioma. The aim of this study was to investigate the metabolic network of C6 cells after exposure to anlotinib and to identify anti-glioma mechanism from the perspective of metabolic reprogramming. Firstly, CCK8 method was used to evaluate the effects of anlotinib on cell proliferation and apoptosis. Secondly, ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS)-based metabolomic and lipidomic were developed to characterize the metabolite and lipid changes in cell and cell culture medium (CCM) caused by anlotinib in the treatment of glioma. As a result, anlotinib had concentration-dependent inhibitory effect with the concentration range. In total, twenty-four and twenty-three disturbed metabolites in cell and CCM responsible for the intervention effect of anlotinib were screened and annotated using UHPLC-HRMS. Altogether, seventeen differential lipids in cell were identified between anlotinib exposure and untreated groups. Metabolic pathways, including amino acid metabolism, energy metabolism, ceramide metabolism, and glycerophospholipid metabolism, were modulated by anlotinib in glioma cell. Overall, anlotinib has an effective treatment against the development and progression of glioma, and these remarkable pathways can generate the key molecular events in cells treated with anlotinib. Future research into the mechanisms underlying the metabolic changes is expected to provide new strategies for treating glioma.

References

Mudassar F, Shen H, ONeill G, Hau E . Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas. J Exp Clin Cancer Res. 2020; 39(1):208. PMC: 7542384. DOI: 10.1186/s13046-020-01724-6. View

Liang L, Rasmussen M, Piening B, Shen X, Chen S, Rost H . Metabolic Dynamics and Prediction of Gestational Age and Time to Delivery in Pregnant Women. Cell. 2020; 181(7):1680-1692.e15. PMC: 7327522. DOI: 10.1016/j.cell.2020.05.002. View

Flavahan W, Drier Y, Liau B, Gillespie S, Venteicher A, Stemmer-Rachamimov A . Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2015; 529(7584):110-4. PMC: 4831574. DOI: 10.1038/nature16490. View

Zaibaq F, Dowdy T, Larion M . Targeting the Sphingolipid Rheostat in Gliomas. Int J Mol Sci. 2022; 23(16). PMC: 9408832. DOI: 10.3390/ijms23169255. View

Yao P, Kang D, Lin R, Ye B, Wang W, Ye Z . Glutamate/glutamine metabolism coupling between astrocytes and glioma cells: neuroprotection and inhibition of glioma growth. Biochem Biophys Res Commun. 2014; 450(1):295-9. DOI: 10.1016/j.bbrc.2014.05.120. View

Karachi A, Dastmalchi F, Mitchell D, Rahman M . Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 2018; 20(12):1566-1572. PMC: 6231207. DOI: 10.1093/neuonc/noy072. View

Liu H, Wang S, Lin J, Lin Z, Li H . Investigation of the lipidomic changes in differentiated glioblastoma cells after drug treatment using MALDI-MS. Talanta. 2021; 233:122570. DOI: 10.1016/j.talanta.2021.122570. View

Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z . Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018; 11(1):120. PMC: 6146601. DOI: 10.1186/s13045-018-0664-7. View

Yamashita D, Bernstock J, Elsayed G, Sadahiro H, Mohyeldin A, Chagoya G . Targeting glioma-initiating cells via the tyrosine metabolic pathway. J Neurosurg. 2020; 134(3):721-732. PMC: 8447888. DOI: 10.3171/2019.11.JNS192028. View

10.

Xu Q, Wu C, Zhu Q, Gao R, Lu J, Valles-Colomer M . Metagenomic and metabolomic remodeling in nonagenarians and centenarians and its association with genetic and socioeconomic factors. Nat Aging. 2023; 2(5):438-452. DOI: 10.1038/s43587-022-00193-0. View

11.

Miller A, Shah R, Pentsova E, Pourmaleki M, Briggs S, DiStefano N . Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019; 565(7741):654-658. PMC: 6457907. DOI: 10.1038/s41586-019-0882-3. View

12.

Xu P, Wang H, Pan H, Chen J, Deng C . Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway. Cancer Chemother Pharmacol. 2022; 89(2):183-196. PMC: 8807469. DOI: 10.1007/s00280-021-04380-5. View

13.

Zong L, Xing J, Liu S, Liu Z, Song F . Cell metabolomics reveals the neurotoxicity mechanism of cadmium in PC12 cells. Ecotoxicol Environ Saf. 2017; 147:26-33. DOI: 10.1016/j.ecoenv.2017.08.028. View

14.

Gaca-Tabaszewska M, Bogusiewicz J, Bojko B . Metabolomic and Lipidomic Profiling of Gliomas-A New Direction in Personalized Therapies. Cancers (Basel). 2022; 14(20). PMC: 9599495. DOI: 10.3390/cancers14205041. View

15.

Strickland M, Stoll E . Metabolic Reprogramming in Glioma. Front Cell Dev Biol. 2017; 5:43. PMC: 5405080. DOI: 10.3389/fcell.2017.00043. View

16.

Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C . Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. Cell. 2020; 182(1):59-72.e15. PMC: 7254001. DOI: 10.1016/j.cell.2020.05.032. View

17.

Wang Z, Wen L, Zhu F, Wang Y, Xie Q, Chen Z . Overexpression of ceramide synthase 1 increases C18-ceramide and leads to lethal autophagy in human glioma. Oncotarget. 2017; 8(61):104022-104036. PMC: 5732784. DOI: 10.18632/oncotarget.21955. View

18.

Hou X, Chen S, Zhang P, Guo D, Wang B . Targeted Arginine Metabolism Therapy: A Dilemma in Glioma Treatment. Front Oncol. 2022; 12:938847. PMC: 9313538. DOI: 10.3389/fonc.2022.938847. View

19.

Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z . Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018; 4(11):1569-1575. PMC: 6248083. DOI: 10.1001/jamaoncol.2018.3039. View

20.

Wang L, Karpova A, Gritsenko M, Kyle J, Cao S, Li Y . Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell. 2021; 39(4):509-528.e20. PMC: 8044053. DOI: 10.1016/j.ccell.2021.01.006. View